Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (421-430 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Cancer|February 4, 2005
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal functionSundar Jagannath, Bart Barlogie, James R Berenson, et al.
Plos One|July 14, 2011
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationDouglas W McMillin, Jake Delmore, Joseph Negri, et al.
Leukemia|January 27, 2022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Cancer|October 17, 2023
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myelomaWenqiang Yan, Jingyu Xu, Huishou Fan, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
British Journal of Haematology|April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myelomaYutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Pageof 87

Showing results (421-430 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Cancer|February 4, 2005
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal functionSundar Jagannath, Bart Barlogie, James R Berenson, et al.
Plos One|July 14, 2011
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationDouglas W McMillin, Jake Delmore, Joseph Negri, et al.
Leukemia|January 27, 2022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Cancer|October 17, 2023
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myelomaWenqiang Yan, Jingyu Xu, Huishou Fan, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
British Journal of Haematology|April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myelomaYutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Pageof 87